# INBX catalysts: Inhibrx Biosciences, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/inbx/catalysts

> Inhibrx Biosciences, Inc. (INBX) has 4 upcoming catalysts. The next is the ozekibart interim data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for INBX?

Inhibrx Biosciences, Inc. (INBX) has 4 upcoming catalysts. The next is the ozekibart interim data readout, Q1 2027. Press release filed with the SEC (EX-99): "The Company expects to announce interim results from these cohorts during the first quarter of 2027." [Calendar and source filings](https://sec-api.dev/companies/inbx/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0002007919-26-000044, https://www.sec.gov/Archives/edgar/data/2007919/000200791926000044/exhibit99106302026.htm (retrieved 2026-11-12). Last confirmed 2026-11-13. Cite: https://sec-api.dev/companies/inbx/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Inhibrx Biosciences, Inc. |
| Ticker | INBX (Nasdaq) |
| SEC CIK | 2007919 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/inbx |

## Cash runway

Cash $199.5M as of 2026-09-30; quarterly burn $34.6M; about 17.3 months of runway at that rate (XBRL company facts, accession 0002007919-26-000059).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 14, 2024 | [Inhibrx Biosciences, Inc. earnings report](https://sec-api.dev/companies/inbx/catalysts) | INBX |  | completed | "Inhibrx Biosciences Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791924000060/exhibit99109302024.htm)) |
| March 17, 2025 | [Inhibrx Biosciences, Inc. earnings report](https://sec-api.dev/companies/inbx/catalysts) | INBX |  | completed | "Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791925000020/exhibit99112312024.htm)) |
| May 14, 2025 | [Inhibrx Biosciences, Inc. earnings report](https://sec-api.dev/companies/inbx/catalysts) | INBX |  | completed | "Inhibrx Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791925000057/exhibit99103312025.htm)) |
| Q3 2025 | [Inhibrx Biosciences, Inc. interim data readout](https://sec-api.dev/companies/inbx/catalysts) | INBX |  | scheduled | "◦Initial data on the colorectal cancer expansion cohort are anticipated in the third quarter of 2025 with interim data from the Ewing sarcoma expansion cohort expected in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791925000057/exhibit99103312025.htm)) |
| August 13, 2025 | [Inhibrx Biosciences, Inc. earnings report](https://sec-api.dev/companies/inbx/catalysts) | INBX |  | completed | "Inhibrx Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791925000083/exhibit99106302025.htm)) |
| September 30, 2025 | [INBRX-109 primary completion](https://sec-api.dev/pdufa/inbrx-109) | INBX | Conventional Chondrosarcoma | completed | "NCT04950075 (Study of INBRX-109 in Conventional Chondrosarcoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor Inhibrx Biosciences, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04950075)) |
| Oct 2025 | [Ozekibart interim data readout](https://sec-api.dev/pdufa/ozekibart) | INBX |  | scheduled | "Interim data on this cohort will be announced with the chondrosarcoma data, which are anticipated by late October 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/2007919/000200791925000081/inhibrx-20250630.htm)) |
| Q4 2025 | [Ordastobart interim data readout](https://sec-api.dev/pdufa/ordastobart) | INBX |  | scheduled | "We expect to announce initial data on Phase 2 during the fourth quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/2007919/000200791925000093/inhibrx-20250930.htm)) |
| Q4 2025 | [KEYTRUDA® (pembrolizumab) interim data readout](https://sec-api.dev/pdufa/pembrolizumab) | INBX |  | scheduled | "•Initial Phase 2 data from the INBRX-106 randomized Phase 2/3 trial in head and neck squamous cell carcinoma in combination with KEYTRUDA® (pembrolizumab) are expected during the fourth quarter of 2025, as well as interim data from the Phase 1/2 checkpoint inhibitor refractory or relapsed non-small cell lung cancer trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791925000083/exhibit99106302025.htm)) |
| October 23, 2025 | [Ozekibart topline data readout](https://sec-api.dev/pdufa/ozekibart) | INBX | advanced or metastatic, unresectable chondrosarcoma and | completed, positive | "On October 23, 2025, Inhibrx announced positive topline results from its registrational trial of ozekibart (INBRX-109) in chondrosarcoma and provided an update on its colorectal cancer and Ewing sarcoma expansion cohorts." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791925000094/exhibit99109302025.htm)) |
| November 14, 2025 | [Inhibrx Biosciences, Inc. earnings report](https://sec-api.dev/companies/inbx/catalysts) | INBX |  | completed | "Inhibrx Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791925000094/exhibit99109302025.htm)) |
| March 19, 2026 | [Inhibrx Biosciences, Inc. earnings report](https://sec-api.dev/companies/inbx/catalysts) | INBX |  | completed | "Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000007/exhibit99112312025.htm)) |
| Q2 2026 | [Ozekibart NDA/BLA submission](https://sec-api.dev/pdufa/ozekibart) | INBX | metastatic or unresectable chondrosarcoma early | scheduled | "◦We expect to submit the Biologics License Application ("BLA") for ozekibart for the treatment of unresectable or metastatic conventional chondrosarcoma to the U.S. Food and Drug Administration ("FDA") early in the second quarter of 2026;" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000007/exhibit99112312025.htm)) |
| Apr 2026 | [Ozekibart NDA/BLA submission](https://sec-api.dev/pdufa/ozekibart) | INBX |  | completed | "◦Additionally, in April 2026, we submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ozekibart in conventional chondrosarcoma; and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000028/exhibit99103312026.htm)) |
| May 11, 2026 | [Ordastobart interim data readout](https://sec-api.dev/pdufa/ordastobart) | INBX |  | completed, positive | "On May 11, 2026, Inhibrx announced positive interim results from its randomized, first-line Phase 2 portion of the HexAgon study." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000020/inhibrx-20260511.htm)) |
| May 14, 2026 | [Inhibrx Biosciences, Inc. earnings report](https://sec-api.dev/companies/inbx/catalysts) | INBX |  | completed | "Inhibrx Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000028/exhibit99103312026.htm)) |
| June 15, 2026 | [Ozekibart NDA/BLA acceptance](https://sec-api.dev/pdufa/ozekibart) | INBX | with unresectable or metastatic conventional chondrosarcoma | completed | "On June 15, 2026, the Company announced that the FDA has accepted for filing its BLA seeking approval of ozekibart for the treatment of patients with unresectable or metastatic conventional chondrosarcoma." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000033/inhibrx-20260615.htm)) |
| Q3 2026 | [Ordastobart trial start](https://sec-api.dev/pdufa/ordastobart) | INBX |  | scheduled | "Inhibrx's plans to begin the Phase 3 portion of the HexAgon study during the third quarter of 2026" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000020/inhibrx-20260511.htm)) |
| August 13, 2026 | [Inhibrx Biosciences, Inc. earnings report](https://sec-api.dev/companies/inbx/catalysts) | INBX |  | completed | "Inhibrx Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000044/exhibit99106302026.htm)) |
| Q4 2026 | [Ozekibart trial start](https://sec-api.dev/pdufa/ozekibart) | INBX |  | scheduled | "◦The Company plans to meet with the FDA in the fourth quarter of 2026 to discuss plans to initiate a first-line registrational trial in CRC as well as the potential for an accelerated regulatory pathway for ozekibart in fourth-line CRC." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000044/exhibit99106302026.htm)) |
| November 13, 2026 | [Inhibrx Biosciences, Inc. earnings report](https://sec-api.dev/companies/inbx/catalysts) | INBX |  | completed | "Inhibrx Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000057/exhibit99109302026.htm)) |
| Q1 2027 | [Ozekibart interim data readout](https://sec-api.dev/pdufa/ozekibart) | INBX |  | scheduled | "The Company expects to announce interim results from these cohorts during the first quarter of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000044/exhibit99106302026.htm)) |
| April 14, 2027 | [Ozekibart PDUFA date](https://sec-api.dev/pdufa/ozekibart) | INBX |  | scheduled | "◦In June 2026, the U.S. Food and Drug Administration (FDA) accepted for filing the Company's biologics license application (BLA) for the potential approval of ozekibart in conventional chondrosarcoma and assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000044/exhibit99106302026.htm)) |
| December 2029 | [Ordastobart primary completion](https://sec-api.dev/pdufa/ordastobart) | INBX |  | scheduled | "NCT06295731 (Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Inhibrx Biosciences, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06295731)) |
| Dec 2029 to Mar 2030 | [Ordastobart topline data readout](https://sec-api.dev/pdufa/ordastobart) | INBX |  | scheduled | "NCT06295731 (Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Inhibrx Biosciences, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06295731)) |

## Drugs

- [INBRX-109](https://sec-api.dev/pdufa/inbrx-109): Conventional Chondrosarcoma
- [Ordastobart](https://sec-api.dev/pdufa/ordastobart): Head and Neck Squamous Cell Carcinoma (HNSCC)
- [Ozekibart](https://sec-api.dev/pdufa/ozekibart): with unresectable or metastatic conventional chondrosarcoma, metastatic or unresectable chondrosarcoma early, metastatic or unresectable chondrosarcoma, we may never, unresectable or metastatic conventional chondrosarcoma, advanced or metastatic, unresectable chondrosarcoma and, advanced or metastatic, unresectable chondrosarcoma

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/inbx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "INBX catalysts: Inhibrx Biosciences, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/inbx/catalysts

```bibtex
@misc{secapidev_companies_inbx_catalysts_20261116,
  title        = {INBX catalysts: Inhibrx Biosciences, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/inbx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_inbx_catalysts_20261116","title":"INBX catalysts: Inhibrx Biosciences, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/inbx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
